Stockwatch: Jam tomorrow
This article was originally published in Scrip
Executive Summary
The Private Securities Litigation Reform Act of 1995, or Forward-Looking Statement Safe Harbor disclaimer as it is better known, advises investors that under such a disclaimer, companies can make financial projections and statements on clinical trial success or approval for their drugs, without fear of repercussion if those statements fail to be true. Additionally, having promised the moon, companies are under no obligation to update investors if they fail to deliver whatever promises were previously made under the Safe Harbor disclaimer.
You may also be interested in...
Stockwatch: Flat Is The New Black For Lilly And Sanofi
A lackluster fourth-quarter earnings season at least didn't get any worse with the reports of Merck, Lilly, Sanofi and GSK. Flat earnings guidance might be considered to be an improvement on guidance cuts, but financial guidance that depends on currency effects and the absence of generic competition may ultimately be unreliable.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.